Solitary pulmonary nodule evaluation of solitary pulmonary nodule: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(18 intermediate revisions by one other user not shown)
Line 5: Line 5:
==Overview==
==Overview==


A hallmark feature in the evaluation of solitary pulmonary nodule is the malignancy risk assessment. The evaluation approach of solitary pulmonary nodule will mainly depend in the initial morphological evaluation of the nodule (size, margins, contours, and growth). Other characteristics, such as: location, clinical features, and distribution may be helpful for the risk assessment, therapeutical management, surveillance, and follow-up of solitary pulmonary nodule. Solitary pulmonary nodule can be divided into 4 risk categories: low risk, intermediate, moderate and high risk. Based upon these risk categories, complementary diagnostic studies and management, include: PET/CT scan, CT scan, non-surgical biopsy, and surgical resection.
A [[hallmark]] feature in the evaluation of pulmonary nodule is the [[Cancer|malignancy]] risk assessment. The evaluation approach for pulmonary nodule will mainly depend in the initial [[Morphology|morphological]] evaluation of the [[Nodule (medicine)|nodule]] (size, margins, contours, and growth). Other characteristics, such as location, clinical features, and distribution may be helpful in the risk assessment, management, surveillance, and follow-up of pulmonary nodule. Pulmonary nodule can be divided into 3 risk categories: low risk, intermediate/moderate, and high risk. Based upon these risk categories, complementary [[Diagnosis|diagnostic]] studies and management include: [[Positron emission tomography|PET]]/[[Computed tomography|CT scan]], [[Computed tomography|CT scan]], non-surgical [[biopsy]], and [[Resection|surgical resection]].


==Evaluation of Solitary Pulmonary Nodule==
==Evaluation of Solitary Pulmonary Nodule==
Line 21: Line 21:
{{familytree | | | C01 | | | | C02 | | | | C01=<div style="width: 17em; padding:1em;text-align:center">'''Step 2A'''<br>'''[[Solitary pulmonary nodule CT|'''Enhanced Computed Tomography''']] </div>|C02=<div style="width: 15em; padding:1em;">'''Step 2B'''<br>'''Surveillance'''</div>}}
{{familytree | | | C01 | | | | C02 | | | | C01=<div style="width: 17em; padding:1em;text-align:center">'''Step 2A'''<br>'''[[Solitary pulmonary nodule CT|'''Enhanced Computed Tomography''']] </div>|C02=<div style="width: 15em; padding:1em;">'''Step 2B'''<br>'''Surveillance'''</div>}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | C03 | | | | | | | | | | | |C03=<div style="width: 10em; padding:0.2em;">'''Imaging evaluation'''</div>}}
{{familytree | | | C03 | | | | | | | | | | | |C03=<div style="width: 10em; padding:0.2em;">[[Solitary pulmonary nodule imaging|'''Imaging evaluation''']]</div>}}
{{familytree|boxstyle= border-top: 0px;| | | C04 | | | | | | | | | | | C04=<div style="width: 17em; padding:1em;text-align:left">'''Location'''<br> ❑ Upper lobe <br> ❑ Lower lobe  <br> ❑ Middle lobe <br>'''Size'''<br> ❑ < 8mm <br> ❑ > 8mm <br>'''Lesion characteristics'''<br>  ❑ Margins (irregular/regular)<br>  ❑ Shape (spiculated/rounded)<br>  ❑ Attenuation </div>}}
{{familytree|boxstyle= border-top: 0px;| | | C04 | | | | | | | | | | | C04=<div style="width: 17em; padding:1em;text-align:left">'''Location'''<br> ❑ Upper lobe <br> ❑ Lower lobe  <br> ❑ Middle lobe <br>'''Size'''<br> ❑ < 8mm <br> ❑ > 8mm <br>'''Lesion characteristics'''<br>  ❑ Margins (irregular/regular)<br>  ❑ Shape (spiculated/rounded)<br>  ❑ Attenuation </div>}}
{{familytree | | | |!| | | | | | | | | | | |}}
{{familytree | | | |!| | | | | | | | | | | |}}
Line 34: Line 34:
{{familytree | | | | | | F01 | | | | | | | F01=<div style="width: 15em; padding:1em;">'''Step 3: [[Solitary pulmonary nodule medical therapy|'''Treatment and Follow-up''']]''' </div>}}
{{familytree | | | | | | F01 | | | | | | | F01=<div style="width: 15em; padding:1em;">'''Step 3: [[Solitary pulmonary nodule medical therapy|'''Treatment and Follow-up''']]''' </div>}}
{{familytree/end}}
{{familytree/end}}
==Malignancy Risk Assessment==
The [[Cancer|malignancy]] risk assessment for pulmonary nodule considers the following factors:<ref name="calculator">Swensen SJ, Silverstein MD, Ilstrup DM, et. al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997 Apr 28;157(8):849-55.</ref>
*Age
*[[Smoking]]
:*Current
:*Never smoker
*[[Cancer]]
:*[[Thoracic|Extrathoracic]] [[cancer]] more than 5 years prior
*[[Nodule (medicine)|Nodule]] diameter
*Spiculation
:*Yes
:*No
*Upper [[Lobe (anatomy)|lobe]]
:*Yes
:*No
*The risk calculator is not validated for [[Patient|patients]] with history of [[cancer]] in the past 5 years.<ref name="calculator">Swensen SJ, Silverstein MD, Ilstrup DM, et. al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997 Apr 28;157(8):849-55.</ref>
The [[Cancer|malignancy]] of pulmonary nodule can be categorized into 3 groups:<ref name="pmid19835344">{{cite journal |vauthors=Albert RH, Russell JJ |title=Evaluation of the solitary pulmonary nodule |journal=Am Fam Physician |volume=80 |issue=8 |pages=827–31 |year=2009 |pmid=19835344 |doi= |url=}}</ref>
'''Low Probability'''
* Usually less than < 5 percent
* The [[Nodule (medicine)|nodule]] size is less than or equal to 4 mm
* The [[Nodule (medicine)|nodule]] size may also be between  4 - 6 mm, with no associated [[Risk factor|risk factors]]
* Observation is suggested
* Observation usually involves [[Radiological|radiologic]] surveillance with serial [[Computed tomography|CT scans]]
'''Intermediate Probability'''
* Between 5 to 65 percent
* The [[Nodule (medicine)|nodule]] size is between 6 - 8 mm
* The [[Nodule (medicine)|nodule]] size is more than > 8 mm with associated [[Risk factor|risk factors]]
*[[Diagnosis|Diagnostic]] testing is indicated: [[Positron emission tomography|Positron emission tomography (PET)]], [[Computed tomography|CT]]-[[Needle aspiration biopsy|FNA]], and [[bronchoscopy]]
'''High Probability'''
* More than > 65 percent
* The [[Nodule (medicine)|nodule]] size is more than > 8 mm with associated [[Risk factor|risk factors]]
*[[Diagnosis|Diagnostic]] testing is indicated: [[Positron emission tomography|Positron emission tomography (PET)]], [[Computed tomography|CT]]-[[Needle aspiration biopsy|FNA]], and [[bronchoscopy]]
*[[Surgery|Surgical]] [[excision]]
The [[patient]] risk assessment of pulmonary nodule can be categorized into 2 groups:<ref name="pmid19835344">{{cite journal |vauthors=Albert RH, Russell JJ |title=Evaluation of the solitary pulmonary nodule |journal=Am Fam Physician |volume=80 |issue=8 |pages=827–31 |year=2009 |pmid=19835344 |doi= |url=}}</ref>
*'''High Risk Patients'''
:*[[Patient]] age is > 35
:* Positive [[smoking]] history
:*[[Male]] [[Patient|patients]]
:* Positive for prior [[Cancer|malignancy]]
:* Other associated [[Risk factor|risk factors]].
*'''Low Risk Patients'''
:*[[Patient]] age < 35
:*No [[smoking]] history
:*[[Female]] [[Patient|patients]]
:*Negative for prior [[Cancer|malignancy]]
:*No associated [[Risk factor|risk factors]]


==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 17:03, 28 June 2019

Pulmonary Nodule Microchapters

Home

Patient Information

Overview

Classification

Causes

Differentiating Pulmonary Nodule from Other Diseases

Epidemiology and Demographics

Screening

Natural history, Complications and Prognosis

Diagnosis

Evaluation of Solitary Pulmonary Nodule

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Solitary pulmonary nodule evaluation of solitary pulmonary nodule On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Solitary pulmonary nodule evaluation of solitary pulmonary nodule

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Solitary pulmonary nodule evaluation of solitary pulmonary nodule

CDC on Solitary pulmonary nodule evaluation of solitary pulmonary nodule

Solitary pulmonary nodule evaluation of solitary pulmonary nodule in the news

Blogs on Solitary pulmonary nodule evaluation of solitary pulmonary nodule

Directions to Hospitals Treating Solitary pulmonary nodule

Risk calculators and risk factors for Solitary pulmonary nodule evaluation of solitary pulmonary nodule

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

A hallmark feature in the evaluation of pulmonary nodule is the malignancy risk assessment. The evaluation approach for pulmonary nodule will mainly depend in the initial morphological evaluation of the nodule (size, margins, contours, and growth). Other characteristics, such as location, clinical features, and distribution may be helpful in the risk assessment, management, surveillance, and follow-up of pulmonary nodule. Pulmonary nodule can be divided into 3 risk categories: low risk, intermediate/moderate, and high risk. Based upon these risk categories, complementary diagnostic studies and management include: PET/CT scan, CT scan, non-surgical biopsy, and surgical resection.

Evaluation of Solitary Pulmonary Nodule

Initial Evaluation Algorithm

 
 
 
 
 
Solitary Pulmonary Nodule Detected
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 1: Assess likelihood of cancer
Mayo Clinic Malignancy Risk Calculator
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2: Review prior films
Is there a growth?
 
No previous films
*Refer to step 2A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes, growing
 
 
 
No, stable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2B
Surveillance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Location
❑ Upper lobe
❑ Lower lobe
❑ Middle lobe
Size
❑ < 8mm
❑ > 8mm
Lesion characteristics
❑ Margins (irregular/regular)
❑ Shape (spiculated/rounded)
❑ Attenuation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Diagnostic Studies
❑ PET/CT scan
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk
❑ < 5%
 
Intermediate risk
❑ 5-65%
 
High risk
❑ > 65%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serial CT scans
 
Non-surgical biopsy
*Refer to Step 3: Treatment and Follow-up
 
Surgical resection
*Refer to Step 3: Treatment and Follow-up
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Malignancy Risk Assessment

The malignancy risk assessment for pulmonary nodule considers the following factors:[1]

  • Current
  • Never smoker
  • Yes
  • No
  • Yes
  • No
  • The risk calculator is not validated for patients with history of cancer in the past 5 years.[1]

The malignancy of pulmonary nodule can be categorized into 3 groups:[2]

Low Probability

  • Usually less than < 5 percent
  • The nodule size is less than or equal to 4 mm
  • The nodule size may also be between 4 - 6 mm, with no associated risk factors
  • Observation is suggested
  • Observation usually involves radiologic surveillance with serial CT scans

Intermediate Probability

High Probability

The patient risk assessment of pulmonary nodule can be categorized into 2 groups:[2]

  • High Risk Patients
  • Low Risk Patients

References

  1. 1.0 1.1 Swensen SJ, Silverstein MD, Ilstrup DM, et. al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997 Apr 28;157(8):849-55.
  2. 2.0 2.1 Albert RH, Russell JJ (2009). "Evaluation of the solitary pulmonary nodule". Am Fam Physician. 80 (8): 827–31. PMID 19835344.